Medifast (MED)
NYSE:MED
MED Stock Chart & Stats
$10.97
-$0.62(-3.78%)
At close: 4:00 PM EST
$10.97
-$0.62(-3.78%)
Day’s Range― - ―
52-Week Range$9.22 - $15.46
Previous CloseN/A
Volume160.90K
Average Volume (3M)236.76K
Market Cap
$107.16M
Enterprise Value$34.65M
Total Cash (Recent Filing)$167.27M
Total Debt (Recent Filing)$16.79M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
May 04, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding10,991,273
10 Day Avg. Volume310,569
30 Day Avg. Volume236,765
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.59
Price to Sales (P/S)0.30
P/FCF Ratio93.90
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue0.09
Enterprise Value/Gross Profit0.13
Enterprise Value/Ebitda23.83
Forecast
1Y Price Target
$12.00Price Target Upside9.39% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.61
Revenue Forecast (FY)$337.50M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet And LiquidityA strong cash position and near-zero leverage provide durable financial flexibility during the turnaround. This cushion supports product development, restructuring and marketing investment without immediate financing risk, lowering solvency pressure while management executes the multi-quarter recovery plan.
Clinically Supported Metabolic-health DifferentiationClinical evidence backing the metabolic synchronization positioning strengthens product differentiation versus commoditized diet offerings. Durable scientific validation can improve retention, enable premium pricing or reimbursement pathways, and underpins the new product launch that management expects to drive profitability improvements long-term.
Early Improvement In Coach Productivity And Field EngagementRising revenue per coach and stronger leadership metrics are meaningful unit-economics signs. If sustained, higher coach productivity can offset a smaller field, boost revenue per customer, and accelerate scalable growth as coach recruitment and retention recover, providing a multi-month runway for top-line stabilization.
Bears Say
Multi-year Revenue Decline And Profitability DeteriorationPersistent top-line declines and the shift from double-digit net margins to a 2025 loss indicate structural demand erosion and lost operating leverage. Recovering margin requires regaining volume or permanently higher prices/efficiency; either path demands sustained execution over many quarters and creates risk to returning to prior profitability levels.
Material Weakening Of Cash Generation And Free Cash FlowSharp cash-flow compression reduces internal funding for marketing, coach incentives and the planned product launch. Even with a large cash balance, low and volatile free cash flow increases the risk that management must cut investment or pursue external financing if the recovery stalls, constraining strategic optionality over the medium term.
Structural Market Disruption From GLP-1 Adoption And Coach AttritionWidespread GLP-1 usage changes customer behavior and reduces demand for traditional coaching-led fuelings, shrinking Medifast's distribution and recurring-consumption model. High coach attrition (down ~40% YoY) erodes the company's primary customer acquisition channel, making rebuilding the network and regaining scale a multi-quarter structural challenge.
Medifast News
MED FAQ
What was Medifast’s price range in the past 12 months?
Medifast lowest stock price was $9.22 and its highest was $15.46 in the past 12 months.
What is Medifast’s market cap?
Medifast’s market cap is $107.16M.
When is Medifast’s upcoming earnings report date?
Medifast’s upcoming earnings report date is May 04, 2026 which is in 36 days.
How were Medifast’s earnings last quarter?
Medifast released its earnings results on Feb 17, 2026. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.82 by $0.27.
Is Medifast overvalued?
According to Wall Street analysts Medifast’s price is currently Undervalued.
Does Medifast pay dividends?
Medifast pays a Quarterly dividend of $1.65 which represents an annual dividend yield of N/A. See more information on Medifast dividends here
What is Medifast’s EPS estimate?
Medifast’s EPS estimate is -0.52.
How many shares outstanding does Medifast have?
Medifast has 10,991,273 shares outstanding.
What happened to Medifast’s price movement after its last earnings report?
Medifast reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.82. Following the earnings report the stock price went down -0.833%.
Which hedge fund is a major shareholder of Medifast?
Currently, no hedge funds are holding shares in MED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medifast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.00 (9.39% Upside)
$12.00 (9.39% Upside)
Blogger Sentiment
Bullish
MED Sentiment 100%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Decreased
By 294.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $178.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.73%
12-Months-Change
Fundamentals
Return on Equity
-8.89%
Trailing 12-Months
Asset Growth
-12.35%
Trailing 12-Months
Company Description
Medifast
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
MED Company Deck
MED Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mix of encouraging operational and strategic early signs (positive coach productivity inflection, stronger coach leadership metrics, clinical validation of the metabolic health positioning, meaningful cost reductions and a strong cash position) alongside significant near-term financial challenges (large YoY revenue decline, a ~41% drop in active earning coaches, compressed gross profit and an $18.1M net loss driven in part by a $12.1M deferred tax valuation allowance). Management provided full-year guidance and a path toward returning to profitability in late 2026, but the magnitude of recent declines and the ongoing market disruption from GLP-1 adoption imply substantial execution risk before recovery is evident in top-line results.View all MED earnings summariesMED Stock 12 Month Forecast
Average Price Target
$12.00
▲(9.39% Upside)
Technical Analysis
Ownership Overview
4.71% Insiders
14.32% Mutual Funds
8.78% Other Institutional Investors
50.77% Public Companies and
Individual Investors